Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

RAGE signaling sustains inflammation and promotes tumor development.

Gebhardt C, Riehl A, Durchdewald M, Németh J, Fürstenberger G, Müller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth PP, Hess J, Angel P.

J Exp Med. 2008 Feb 18;205(2):275-85. doi: 10.1084/jem.20070679. Epub 2008 Jan 21.

2.

Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis.

Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ.

Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):652-6. doi: 10.1073/pnas.0708594105. Epub 2008 Jan 4.

3.

Creating immune privilege: active local suppression that benefits friends, but protects foes.

Mellor AL, Munn DH.

Nat Rev Immunol. 2008 Jan;8(1):74-80. Review. Erratum in: Nat Rev Immunol. 2008 Feb;8(2):160.

PMID:
18064049
4.

Adaptive immunity maintains occult cancer in an equilibrium state.

Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD.

Nature. 2007 Dec 6;450(7171):903-7. Epub 2007 Nov 18.

PMID:
18026089
5.

IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells.

Hill M, Tanguy-Royer S, Royer P, Chauveau C, Asghar K, Tesson L, Lavainne F, Rémy S, Brion R, Hubert FX, Heslan M, Rimbert M, Berthelot L, Moffett JR, Josien R, Grégoire M, Anegon I.

Eur J Immunol. 2007 Nov;37(11):3054-62.

6.
7.

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH.

J Clin Invest. 2007 Sep;117(9):2570-82.

8.

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.

Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC.

Cancer Res. 2007 Aug 1;67(15):7082-7.

9.

Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice.

Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Astelbauer F, Miu J, McQuillan JA, Stocker R, Jermiin LS, Hunt NH.

Gene. 2007 Jul 1;396(1):203-13. Epub 2007 Apr 18. Erratum in: Gene. 2010 Oct 1;465(1-2):66.

PMID:
17499941
10.

Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells.

Manlapat AK, Kahler DJ, Chandler PR, Munn DH, Mellor AL.

Eur J Immunol. 2007 Apr;37(4):1064-71.

11.

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.

Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH.

Cancer Res. 2007 Jan 15;67(2):792-801.

12.

Immune privilege in sites of chronic infection: Leishmania and regulatory T cells.

Peters N, Sacks D.

Immunol Rev. 2006 Oct;213:159-79. Review.

PMID:
16972903
13.

The tumor-draining lymph node as an immune-privileged site.

Munn DH, Mellor AL.

Immunol Rev. 2006 Oct;213:146-58. Review.

PMID:
16972902
14.

Immune resistance orchestrated by the tumor microenvironment.

Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H.

Immunol Rev. 2006 Oct;213:131-45. Review.

PMID:
16972901
15.

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

Muller AJ, Scherle PA.

Nat Rev Cancer. 2006 Aug;6(8):613-25. Review. Erratum in: Nat Rev Cancer. 2006 Sep;6(9):742.

PMID:
16862192
16.

Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.

Munn DH.

Curr Opin Immunol. 2006 Apr;18(2):220-5. Epub 2006 Feb 7. Review.

PMID:
16460921
17.

Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.

Wingender G, Garbi N, Schumak B, Jüngerkes F, Endl E, von Bubnoff D, Steitz J, Striegler J, Moldenhauer G, Tüting T, Heit A, Huster KM, Takikawa O, Akira S, Busch DH, Wagner H, Hämmerling GJ, Knolle PA, Limmer A.

Eur J Immunol. 2006 Jan;36(1):12-20.

20.

Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells.

Fallarino F, Orabona C, Vacca C, Bianchi R, Gizzi S, Asselin-Paturel C, Fioretti MC, Trinchieri G, Grohmann U, Puccetti P.

Int Immunol. 2005 Nov;17(11):1429-38. Epub 2005 Sep 19.

PMID:
16172135

Supplemental Content

Support Center